Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Bevacizumab"" wg kryterium: Temat


Tytuł:
Ethnic differences on long term outcomes of polypoidal choroidal vasculopathy after predominantly bevacizumab monotherapy.
Autorzy:
Yap A; Department of Ophthalmology, The University of Auckland, 85 Park Road, Grafton, Auckland, 1051, New Zealand. .
Wang N; Department of Ophthalmology, The University of Auckland, 85 Park Road, Grafton, Auckland, 1051, New Zealand.
Squirrell D; Department of Ophthalmology, The University of Auckland, 85 Park Road, Grafton, Auckland, 1051, New Zealand.; Department of Ophthalmology, Auckland District Health Board, Auckland, New Zealand.
Pokaż więcej
Źródło:
BMC ophthalmology [BMC Ophthalmol] 2022 Jul 28; Vol. 22 (1), pp. 325. Date of Electronic Publication: 2022 Jul 28.
Typ publikacji:
Journal Article
MeSH Terms:
Angiogenesis Inhibitors*/therapeutic use
Bevacizumab*/therapeutic use
Choroid*/blood supply
Photochemotherapy*/methods
Cohort Studies ; Humans ; Intravitreal Injections ; Retrospective Studies ; Tomography, Optical Coherence ; Vascular Endothelial Growth Factor A
Czasopismo naukowe
Tytuł:
Intravitreal dexamethasone versus bevacizumab in Aboriginal and Torres Strait Islander patients with diabetic macular oedema: The OASIS study (a randomised control trial).
Autorzy:
Meyer J; Lions Eye Institute, Perth, Western Australia, Australia.; Lions Outback Vision, Lions Eye Institute, Broome, Werstern Australia, Australia.
Fry C; Lions Eye Institute, Perth, Western Australia, Australia.
Turner A; Lions Eye Institute, Perth, Western Australia, Australia.; Lions Outback Vision, Lions Eye Institute, Broome, Werstern Australia, Australia.; Centre for Ophthalmology and Vision Sciences, University of Western Australia, Perth, Western Australia, Australia.
Razavi H; Lions Eye Institute, Perth, Western Australia, Australia.; Lions Outback Vision, Lions Eye Institute, Broome, Werstern Australia, Australia.; Centre for Ophthalmology and Vision Sciences, University of Western Australia, Perth, Western Australia, Australia.
Pokaż więcej
Źródło:
Clinical & experimental ophthalmology [Clin Exp Ophthalmol] 2022 Jul; Vol. 50 (5), pp. 522-533. Date of Electronic Publication: 2022 Apr 08.
Typ publikacji:
Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Bevacizumab*/therapeutic use
Dexamethasone*/therapeutic use
Diabetes Mellitus*
Diabetic Retinopathy*/complications
Diabetic Retinopathy*/diagnosis
Diabetic Retinopathy*/drug therapy
Macular Edema*/diagnosis
Macular Edema*/drug therapy
Macular Edema*/etiology
Adult ; Cataract/complications ; Drug Implants/therapeutic use ; Glucocorticoids/therapeutic use ; Humans ; Intravitreal Injections ; Native Hawaiian or Other Pacific Islander ; Prospective Studies ; Pyrroles ; Vinyl Compounds ; Visual Acuity ; Western Australia
Czasopismo naukowe
Tytuł:
ALOX12: A Novel Insight in Bevacizumab Response, Immunotherapy Effect, and Prognosis of Colorectal Cancer.
Autorzy:
Weng S; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.; Interventional Institute of Zhengzhou University, Zhengzhou, China.; Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, China.
Liu Z; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.; Interventional Institute of Zhengzhou University, Zhengzhou, China.; Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, China.
Xu H; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.; Interventional Institute of Zhengzhou University, Zhengzhou, China.; Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, China.
Ge X; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Ren Y; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Dang Q; Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Liu L; Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhang J; Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Luo P; Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Ren J; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Han X; Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.; Interventional Institute of Zhengzhou University, Zhengzhou, China.; Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, China.
Pokaż więcej
Źródło:
Frontiers in immunology [Front Immunol] 2022 Jun 27; Vol. 13, pp. 910582. Date of Electronic Publication: 2022 Jun 27 (Print Publication: 2022).
Typ publikacji:
Journal Article
MeSH Terms:
Arachidonate 12-Lipoxygenase*/genetics
Arachidonate 12-Lipoxygenase*/metabolism
Bevacizumab*/therapeutic use
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/genetics
Colorectal Neoplasms*/metabolism
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; DNA Copy Number Variations ; Humans ; Immunotherapy ; Prognosis
Czasopismo naukowe
Tytuł:
Rate of Curative Surgery in Real-world Patients with Unresectable Metastatic Colorectal Cancer Treated with FOLFOXIRI ± Bevacizumab: A Western Canadian Province Experience.
Autorzy:
Bhatti T; College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
Moser M; Department of Surgery, University of Saskatchewan, Saskatoon, SK, Canada.
Tan KT; Univeristy of Toronto, Toronto, ON, Canada.
Chalchal H; Allan Blair Cancer Centre, Regina, SK, Canada.
Souied O; Allan Blair Cancer Centre, Regina, SK, Canada.
Le D; Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, Canada.
Shaw J; Department of Surgery, University of Saskatchewan, Saskatoon, SK, Canada.
Zaidi A; Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, Canada.
Gill D; Department of Surgery, University of Saskatchewan, Saskatoon, SK, Canada.
Ahmed S; Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, Canada. .
Pokaż więcej
Źródło:
Journal of gastrointestinal cancer [J Gastrointest Cancer] 2022 Jun; Vol. 53 (2), pp. 427-433. Date of Electronic Publication: 2021 Mar 29.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Bevacizumab*/therapeutic use
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/surgery
Camptothecin/analogs & derivatives ; Camptothecin/therapeutic use ; Cohort Studies ; Female ; Fluorouracil/therapeutic use ; Humans ; Leucovorin/therapeutic use ; Male ; Middle Aged ; Organoplatinum Compounds/therapeutic use ; Saskatchewan
SCR Protocol:
FOLFOXIRI protocol
Czasopismo naukowe
Tytuł:
The combination of MnO 2 @Lipo-coated gefitinib and bevacizumab inhibits the development of non-small cell lung cancer.
Autorzy:
Zhang J; Department of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, School of Medicine, Cancer Center, Zhejiang University, Hangzhou, China.
Xu L; Department of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, School of Medicine, Cancer Center, Zhejiang University, Hangzhou, China.
Hu H; Department of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, School of Medicine, Cancer Center, Zhejiang University, Hangzhou, China.
Chen E; Department of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, School of Medicine, Cancer Center, Zhejiang University, Hangzhou, China.
Pokaż więcej
Źródło:
Drug delivery [Drug Deliv] 2022 Dec; Vol. 29 (1), pp. 466-477.
Typ publikacji:
Journal Article
MeSH Terms:
Bevacizumab/*pharmacology
Carcinoma, Non-Small-Cell Lung/*pathology
Gefitinib/*pharmacology
Lung Neoplasms/*pathology
Manganese Compounds/*chemistry
Nanotubes/*chemistry
Oxides/*chemistry
Animals ; Antineoplastic Agents/pharmacology ; Apoptosis/drug effects ; Bevacizumab/administration & dosage ; Cell Line, Tumor ; Cell Survival/drug effects ; Chemistry, Pharmaceutical ; Delayed-Action Preparations ; Drug Carriers/chemistry ; Drug Combinations ; Drug Liberation ; Gefitinib/administration & dosage ; Humans ; Hydrogen-Ion Concentration ; Mice ; Mice, Inbred BALB C ; Particle Size ; Surface Properties ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł:
Genetic Variants of Complement Factor H Y402H (rs1061170), C2 R102G (rs2230199), and C3 E318D (rs9332739) and Response to Intravitreal Anti-VEGF Treatment in Patients with Exudative Age-Related Macular Degeneration.
Autorzy:
Kubicka-Trząska A; Clinic of Ophtalmology and Ocular Oncology, Department of Ophtalmology, Faculty of Medicine, Jagiellonian University Medical College, 31-501 Krakow, Poland.
Żuber-Łaskawiec K; Clinic of Ophtalmology and Ocular Oncology, Department of Ophtalmology, Faculty of Medicine, Jagiellonian University Medical College, 31-501 Krakow, Poland.
Dziedzina S; Molecular Biology and Clinical Genetics Unit, Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, 31-501 Krakow, Poland.
Sanak M; Molecular Biology and Clinical Genetics Unit, Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, 31-501 Krakow, Poland.
Romanowska-Dixon B; Clinic of Ophtalmology and Ocular Oncology, Department of Ophtalmology, Faculty of Medicine, Jagiellonian University Medical College, 31-501 Krakow, Poland.
Karska-Basta I; Clinic of Ophtalmology and Ocular Oncology, Department of Ophtalmology, Faculty of Medicine, Jagiellonian University Medical College, 31-501 Krakow, Poland.
Pokaż więcej
Źródło:
Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2022 May 13; Vol. 58 (5). Date of Electronic Publication: 2022 May 13.
Typ publikacji:
Journal Article
MeSH Terms:
Bevacizumab*/therapeutic use
Complement Factor H*/genetics
Macular Degeneration*/drug therapy
Macular Degeneration*/genetics
Genotype ; Humans ; Polymorphism, Single Nucleotide
Czasopismo naukowe
Tytuł:
A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers.
Autorzy:
Sinn A; Early Phase Clinical Unit Berlin, Parexel International GmbH. Berlin, Germany.
García-Alvarado F; Medical Department, mAbxience Research S.L. Madrid, Spain.
Gonzalez V; Medical Department, mAbxience Research S.L. Madrid, Spain.
Huerga C; Medical Department, mAbxience Research S.L. Madrid, Spain.
Bullo F; Medical Department, mAbxience Research S.L. Madrid, Spain.
Pokaż więcej
Źródło:
British journal of clinical pharmacology [Br J Clin Pharmacol] 2022 Mar; Vol. 88 (3), pp. 1063-1073. Date of Electronic Publication: 2021 Sep 04.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Bevacizumab*/adverse effects
Bevacizumab*/pharmacokinetics
Biosimilar Pharmaceuticals*/adverse effects
Biosimilar Pharmaceuticals*/pharmacokinetics
Area Under Curve ; Double-Blind Method ; Healthy Volunteers ; Humans ; Male ; Therapeutic Equivalency
Czasopismo naukowe
Tytuł:
Bevacizumab and aflibercept in second-line metastatic colorectal cancer: 12 years of experience.
Autorzy:
Claramunt García R; Pharmacy Department, Hospital Universitario de Jaén, Avd. Ejercito Español, nº 10, CP. 23007, Jaén, Spain.
Muñoz Cid CL; Pharmacy Department, Hospital Universitario de Jaén, Avd. Ejercito Español, nº 10, CP. 23007, Jaén, Spain.
Sánchez Ruiz A; Pharmacy Department, Hospital Alto Guadalquivir, Jaén, Spain.
Marín Pozo JF; Pharmacy Department, Hospital Universitario de Jaén, Avd. Ejercito Español, nº 10, CP. 23007, Jaén, Spain.
Pokaż więcej
Źródło:
European journal of clinical pharmacology [Eur J Clin Pharmacol] 2022 Feb; Vol. 78 (2), pp. 287-291. Date of Electronic Publication: 2021 Oct 18.
Typ publikacji:
Journal Article; Observational Study
MeSH Terms:
Bevacizumab/*therapeutic use
Colorectal Neoplasms/*drug therapy
Receptors, Vascular Endothelial Growth Factor/*therapeutic use
Recombinant Fusion Proteins/*therapeutic use
Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bevacizumab/administration & dosage ; Bevacizumab/adverse effects ; Colorectal Neoplasms/pathology ; Female ; Fluorouracil/therapeutic use ; Humans ; Leucovorin/therapeutic use ; Male ; Middle Aged ; Neoplasm Metastasis ; Organoplatinum Compounds/therapeutic use ; Progression-Free Survival ; Receptors, Vascular Endothelial Growth Factor/administration & dosage ; Recombinant Fusion Proteins/administration & dosage ; Recombinant Fusion Proteins/adverse effects ; Retrospective Studies
SCR Protocol:
Folfox protocol
Czasopismo naukowe
Tytuł:
The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Autorzy:
Liu M; Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.; Jiangxi Medical College, Nanchang University, Nanchang, China.
Luo N; Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.; Jiangxi Medical College, Nanchang University, Nanchang, China.
Fang Z; Jiangxi Medical College, Nanchang University, Nanchang, China.; Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Liu Q; Jiangxi Medical College, Nanchang University, Nanchang, China.; Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Yi F; Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Wei Y; Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Zhang X; Department of Respiratory Diseases, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Zhang W; Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Pokaż więcej
Źródło:
Journal of clinical pharmacy and therapeutics [J Clin Pharm Ther] 2022 Feb; Vol. 47 (2), pp. 157-167. Date of Electronic Publication: 2021 Oct 06.
Typ publikacji:
Journal Article; Meta-Analysis; Review
MeSH Terms:
Antineoplastic Agents/*therapeutic use
Bevacizumab/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Pemetrexed/*therapeutic use
Age Factors ; Aged ; Aged, 80 and over ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bevacizumab/administration & dosage ; Bevacizumab/adverse effects ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Drug Combinations ; Female ; Humans ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Staging ; Pemetrexed/administration & dosage ; Pemetrexed/adverse effects ; Progression-Free Survival ; Randomized Controlled Trials as Topic ; Sex Factors
Czasopismo naukowe
Tytuł:
Response to 1-Year Fixed-Regimen Bevacizumab Therapy in Treatment-Naïve DME Patients: Assessment by OCT Angiography.
Autorzy:
Hunt M; Chair and Department of Ophthalmology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-760 Katowice, Poland.; Department of Ophthalmology, District Railway Hospital in Katowice, 40-760 Katowice, Poland.
Teper S; Chair and Department of Ophthalmology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-760 Katowice, Poland.; Department of Ophthalmology, District Railway Hospital in Katowice, 40-760 Katowice, Poland.
Wylęgała A; Health Promotion and Obesity Management Unit, Department of Pathophysiology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Poland.
Wylęgała E; Chair and Department of Ophthalmology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-760 Katowice, Poland.; Department of Ophthalmology, District Railway Hospital in Katowice, 40-760 Katowice, Poland.
Pokaż więcej
Źródło:
Journal of diabetes research [J Diabetes Res] 2022 Feb 21; Vol. 2022, pp. 3547461. Date of Electronic Publication: 2022 Feb 21 (Print Publication: 2022).
Typ publikacji:
Journal Article
MeSH Terms:
Bevacizumab/*pharmacology
Diabetic Retinopathy/*drug therapy
Aged ; Aged, 80 and over ; Analysis of Variance ; Angiogenesis Inhibitors/metabolism ; Angiogenesis Inhibitors/pharmacology ; Angiogenesis Inhibitors/therapeutic use ; Bevacizumab/metabolism ; Bevacizumab/therapeutic use ; Diabetic Retinopathy/physiopathology ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies ; Qualitative Research ; Statistics, Nonparametric ; Tomography, Optical Coherence/methods ; Tomography, Optical Coherence/statistics & numerical data
Czasopismo naukowe
Tytuł:
Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma.
Autorzy:
Lee YP; Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.; Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
Jung HA; Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.
Lee MS; Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.; Division of Oncology/Hematology, Department of Internal Medicine, Soonchunhyang University Hospital Cheonan, Suncheonhyang 6-gil, Dongnam-gu, Cheonan-si, Chungcheongnam-do, Republic of Korea.
Choi JW; Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.
Kong DS; Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.
Seol HJ; Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.
Nam DH; Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.
Lee JI; Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea. .
Lee SH; Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea. .
Pokaż więcej
Źródło:
Journal of neuro-oncology [J Neurooncol] 2022 Feb; Vol. 156 (3), pp. 541-549. Date of Electronic Publication: 2022 Jan 30.
Typ publikacji:
Journal Article
MeSH Terms:
Bevacizumab*/therapeutic use
Brain Neoplasms*/pathology
Brain Neoplasms*/therapy
Glioma*/pathology
Glioma*/therapy
Irinotecan*/therapeutic use
Radiosurgery*
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemoradiotherapy ; Humans ; Neoplasm Grading ; Retrospective Studies ; Treatment Failure ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Autorzy:
Mettu NB; Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
Ou FS; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
Zemla TJ; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
Halfdanarson TR; Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
Lenz HJ; Division of Medical Oncology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles.
Breakstone RA; Department of Medical Oncology, Lifespan Cancer Institute, Brown University, Providence, Rhode Island.
Boland PM; Department of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick.
Crysler OV; Department of Medical Oncology, University of Michigan, Ann Arbor.
Wu C; Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia.
Nixon AB; Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
Bolch E; Department of Gastrointestinal Oncology Clinical Research, Duke University Medical Center, Durham, North Carolina.
Niedzwiecki D; Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina.
Elsing A; Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
Hurwitz HI; Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.; Product Development Oncology, Genentech Inc, South San Francisco, California.
Fakih MG; Department of Medical Oncology, City of Hope National Medical Center, Duarte, California.
Bekaii-Saab T; Division of Medical Oncology, Mayo Clinic, Phoenix, Arizona.
Pokaż więcej
Źródło:
JAMA network open [JAMA Netw Open] 2022 Feb 01; Vol. 5 (2), pp. e2149040. Date of Electronic Publication: 2022 Feb 01.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/mortality
Colorectal Neoplasms*/pathology
Antibodies, Monoclonal, Humanized/*therapeutic use
Antineoplastic Agents/*therapeutic use
Bevacizumab/*therapeutic use
Capecitabine/*therapeutic use
Aged ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bevacizumab/administration & dosage ; Bevacizumab/adverse effects ; Capecitabine/administration & dosage ; Capecitabine/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Progression-Free Survival
Czasopismo naukowe
Tytuł:
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature.
Autorzy:
Lombardi P; Department of Oncology, Università degli Studi di Torino, Turin, Italy; Phase 1 Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome.
Rossini D; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Crespi V; Department of Oncology, Università degli Studi di Torino, Turin, Italy.
Germani MM; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Bergamo F; Medical Oncology Unit 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Pietrantonio F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Santini D; Department of Medical Oncology, University Campus Biomedico, Roma, Italy.
Allegrini G; Department of Oncology, Division of Medical Oncology, Azienda USL Toscana Nord Ovest, Livorno, Italy.
Daniel F; Medical Oncology Unit 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Pagani F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Antoniotti C; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Zaniboni A; Medical Oncology Unit, Poliambulanza Foundation, Brescia, Italy.
Conca V; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Latiano TP; Oncology Unit, Foundation IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
Boccaccino A; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Passardi A; Department of Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) 'Dino Amadori', Meldola, Italy.
Tamburini E; Oncology Unit, Ospedale degli Infermi, Rimini, Italy; Oncology Department and Palliative Care, Cardinale Panico Tricase City Hospital, Tricase, Italy.
Masi G; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Di Maio M; Department of Oncology, Università degli Studi di Torino, Turin, Italy; Azienda Ospedaliera Ordine Mauriziano di Torino, Turin, Italy. Electronic address: .
Cremolini C; Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Pokaż więcej
Źródło:
Cancer treatment reviews [Cancer Treat Rev] 2022 Feb; Vol. 103, pp. 102326. Date of Electronic Publication: 2021 Dec 23.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Bevacizumab/*adverse effects
Colorectal Neoplasms/*drug therapy
Colorectal Neoplasms/*mortality
Hypertension/*chemically induced
Aged ; Angiogenesis Inhibitors/administration & dosage ; Angiogenesis Inhibitors/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bevacizumab/administration & dosage ; Clinical Trials, Phase III as Topic ; Female ; Humans ; Male ; Middle Aged ; Prognosis ; Progression-Free Survival ; Randomized Controlled Trials as Topic ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Central retinal thickness changes and risk of neovascular glaucoma after intravitreal bevacizumab injection in patients with central retinal vein occlusion.
Autorzy:
Lee YH; Department of Ophthalmology, Keimyung University School of Medicine, 1095 Dalgubeol-daero, Dalseo-gu, Daegu, 42601, Republic of Korea.
Kim YC; Department of Ophthalmology, Keimyung University School of Medicine, 1095 Dalgubeol-daero, Dalseo-gu, Daegu, 42601, Republic of Korea. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Feb 08; Vol. 12 (1), pp. 2051. Date of Electronic Publication: 2022 Feb 08.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Angiogenesis Inhibitors/*therapeutic use
Bevacizumab/*therapeutic use
Glaucoma, Neovascular/*epidemiology
Macular Edema/*drug therapy
Retinal Vein Occlusion/*therapy
Aged ; Angiogenesis Inhibitors/administration & dosage ; Bevacizumab/administration & dosage ; Female ; Humans ; Intravitreal Injections ; Male ; Middle Aged ; Retrospective Studies ; Vascular Endothelial Growth Factor A/antagonists & inhibitors
Czasopismo naukowe
Tytuł:
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS- mutated non-small cell lung cancer with STK11 , KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial.
Autorzy:
West HJ; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA .
McCleland M; Genentech Inc, South San Francisco, California, USA.
Cappuzzo F; Oncology Department, Istituto Nazionale Tumori 'Regina Elena', Rome, Italy.
Reck M; Department of Thoracic Oncology, LungenClinic Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.
Mok TS; State Key Laboratory of Translational Oncology, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China.
Jotte RM; Department of Medical Oncology, Rocky Mountain Cancer Centers, Denver, Colorado, USA.; US Oncology, Houston, Texas, USA.
Nishio M; Thoracic Medical Oncology Department, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Kim E; Genentech Inc, South San Francisco, California, USA.
Morris S; Product Development Medical Affairs, F Hoffmann-La Roche Ltd, Basel, Switzerland.
Zou W; Genentech Inc, South San Francisco, California, USA.
Shames D; Genentech Inc, South San Francisco, California, USA.
Das Thakur M; Genentech Inc, South San Francisco, California, USA.
Shankar G; Genentech Inc, South San Francisco, California, USA.
Socinski MA; Thoracic Oncology, AdventHealth Cancer Institute, Orlando, Florida, USA.
Pokaż więcej
Źródło:
Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Feb; Vol. 10 (2).
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
AMP-Activated Protein Kinase Kinases/*metabolism
Antibodies, Monoclonal, Humanized/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Bevacizumab/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Kelch-Like ECH-Associated Protein 1/*metabolism
Lung Neoplasms/*drug therapy
Tumor Suppressor Protein p53/*metabolism
Adult ; Antibodies, Monoclonal, Humanized/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Bevacizumab/pharmacology ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Humans ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Middle Aged ; Mutation ; Prognosis ; Progression-Free Survival ; Retrospective Studies
Czasopismo naukowe
Tytuł:
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab.
Autorzy:
Hummel M; Viatris Inc, Morgantown, WV, USA.
Bosje T; PRA Health Sciences, Groningen, The Netherlands.
Shaw A; Viatris Inc, Morgantown, WV, USA.
Liu MS; Viatris Inc, Morgantown, WV, USA.
Barve A; Viatris Inc, Canonsburg, PA, USA.
Kothekar M; Biocon Research Ltd (Now With Sun Pharma Advanced Research Company, Mumbai, India), Bangalore, India.
Socinski MA; AdventHealth Cancer Institute, Orlando, FL, USA.
Waller CF; Department of Haematology, Oncology and Stem Cell Transplantation, University Medical Centre Freiburg and Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany. .
Pokaż więcej
Źródło:
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2022 Feb; Vol. 148 (2), pp. 487-496. Date of Electronic Publication: 2021 Apr 17.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
MeSH Terms:
Bevacizumab/*pharmacokinetics
Biosimilar Pharmaceuticals/*pharmacokinetics
Adolescent ; Adult ; Bevacizumab/chemistry ; Biosimilar Pharmaceuticals/chemistry ; Double-Blind Method ; Drug Compounding/methods ; Drug Compounding/standards ; Europe ; Healthy Volunteers ; Humans ; Male ; Middle Aged ; Netherlands ; Therapeutic Equivalency ; United States ; Young Adult
Czasopismo naukowe
Tytuł:
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study).
Autorzy:
Seto T; Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan .
Nosaki K; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Shimokawa M; Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Toyozawa R; Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Sugawara S; Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan.
Hayashi H; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Murakami H; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Kato T; Department of Respiratory Medicine, Kanagawa Cancer Center, Yokohama, Japan.
Niho S; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Saka H; Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center 4-1-1, Nagoya, Japan.
Oki M; Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center 4-1-1, Nagoya, Japan.
Yoshioka H; Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata, Japan.
Okamoto I; Research Institute for Diseases of the Chest, Kyushu University Hospital, Fukuoka, Japan.
Daga H; Department of Clinical Oncology, Osaka City General Hospital, Osaka, Japan.
Azuma K; Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University, Kurume, Japan.
Tanaka H; Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
Nishino K; Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Tohnai R; Department of Thoracic Oncology, Hyogo Cancer Center, Akashi, Japan.
Yamamoto N; Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
Nakagawa K; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Pokaż więcej
Źródło:
Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Feb; Vol. 10 (2).
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal, Humanized/*therapeutic use
Bevacizumab/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Immune Checkpoint Inhibitors/*therapeutic use
Lung Neoplasms/*drug therapy
Adult ; Aged ; Antibodies, Monoclonal, Humanized/pharmacology ; Bevacizumab/pharmacology ; Female ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Male ; Middle Aged
Czasopismo naukowe
Tytuł:
Efficacy and safety of standard of care with/without bevacizumab for platinum-resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023.
Autorzy:
Shoji T; Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Iwate, Japan.
Enomoto T; Department of Obstetrics and Gynecology, Niigata University School of Medicine, Niigata, Japan.
Abe M; Department of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan.
Okamoto A; Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.
Nagasawa T; Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Iwate, Japan.
Oishi T; Department of Obstetrics and Gynecology, Tottori University School of Medicine, Tottori, Japan.
Nagase S; Department of Obstetrics and Gynecology, Faculty of Medicine, Yamagata University, Yamagata, Japan.
Mori M; Department of Gynecology, Aichi Cancer Center Hospital, Aichi, Japan.
Inokuchi Y; Department of Biostatistics, Kitasato Academic Research Organization, Kitasato University, Tokyo, Japan.
Kamiura S; Department of Gynecologic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Komiyama S; Department of Obstetrics and Gynecology, Faculty of Medicine, Toho University, Tokyo, Japan.
Takeshima N; Department of Gynecology, Cancer Institute Hospital, Tokyo, Japan.
Sugiyama T; Department of Obstetrics and Gynecology, St. Mary's Hospital, Fukuoka, Japan.
Pokaż więcej
Źródło:
Cancer science [Cancer Sci] 2022 Jan; Vol. 113 (1), pp. 240-250. Date of Electronic Publication: 2021 Nov 18.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Antineoplastic Agents/*administration & dosage
Bevacizumab/*administration & dosage
Drug Resistance, Neoplasm/*drug effects
Fallopian Tube Neoplasms/*drug therapy
Ovarian Neoplasms/*drug therapy
Peritoneal Neoplasms/*drug therapy
Aged ; Antineoplastic Agents/adverse effects ; Bevacizumab/adverse effects ; Bevacizumab/pharmacology ; Female ; Humans ; Middle Aged ; Platinum/therapeutic use ; Standard of Care ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Repeated superselective intraarterial bevacizumab after blood brain barrier disruption for newly diagnosed glioblastoma: a phase I/II clinical trial.
Autorzy:
Patel NV; Department of Neurosurgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Lenox Hill Hospital, New York, NY, USA. .
Wong T; Department of Neurosurgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Lenox Hill Hospital, New York, NY, USA.
Fralin SR; Department of Neurosurgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Lenox Hill Hospital, New York, NY, USA.
Li M; Department of Neurosurgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Lenox Hill Hospital, New York, NY, USA.
McKeown A; Department of Neurosurgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Lenox Hill Hospital, New York, NY, USA.
Gruber D; Department of Neurology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Lenox Hill Hospital, New York, NY, USA.
D'Amico RS; Department of Neurosurgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Lenox Hill Hospital, New York, NY, USA.
Patsalides A; Department of Radiology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA.
Tsiouris A; Department of Radiology, Weill Cornell Medical Center, New York Presbyterian Hospital, New York, NY, USA.
Stefanov DG; Biostatistics Unit, The Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA.
Flores O; Department of Radiology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA.
Zlochower A; Department of Radiology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, NY, USA.
Filippi CG; Department of Radiology, Tufts University School of Medicine, Boston, MA, USA.
Ortiz R; Department of Neurosurgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Lenox Hill Hospital, New York, NY, USA.
Langer DJ; Department of Neurosurgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Lenox Hill Hospital, New York, NY, USA.
Boockvar JA; Department of Neurosurgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Lenox Hill Hospital, New York, NY, USA.
Pokaż więcej
Źródło:
Journal of neuro-oncology [J Neurooncol] 2021 Nov; Vol. 155 (2), pp. 117-124. Date of Electronic Publication: 2021 Oct 03.
Typ publikacji:
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
MeSH Terms:
Bevacizumab*/administration & dosage
Bevacizumab*/adverse effects
Blood-Brain Barrier*/pathology
Brain Neoplasms*/drug therapy
Glioblastoma*/drug therapy
Adult ; Aged ; Drug Administration Schedule ; Humans ; Infusions, Intra-Arterial ; Middle Aged ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Oral mucosal pseudotumor - Novelty complication in patient undergoing bevacizumab therapy.
Autorzy:
Kudva A; Department of Oral and Maxillofacial Surgery, Manipal College of Dental Sciences, Manipal, Manipal Academy of Higher Education, 576104 Manipal, Karnataka, India. Electronic address: .
Koshy J; Department of Oral and Maxillofacial Surgery, Manipal College of Dental Sciences, Manipal, Manipal Academy of Higher Education, 576104 Manipal, Karnataka, India. Electronic address: .
Jacob JG; Department of Oral and Maxillofacial Surgery, Manipal College of Dental Sciences, Manipal, Manipal Academy of Higher Education, 576104 Manipal, Karnataka, India.
Pokaż więcej
Źródło:
Oral oncology [Oral Oncol] 2021 Nov; Vol. 122, pp. 105543. Date of Electronic Publication: 2021 Sep 27.
Typ publikacji:
Case Reports; Letter
MeSH Terms:
Bevacizumab*/adverse effects
Bevacizumab*/therapeutic use
Cholangiocarcinoma/*drug therapy
Jaw Diseases/*chemically induced
Osteonecrosis/*chemically induced
Humans ; Male ; Middle Aged ; Vascular Endothelial Growth Factor A/antagonists & inhibitors
Raport

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies

Prześlij opinię

Twoje opinie są dla nas bardzo ważne i mogą być niezwykle pomocne w pokazaniu nam, gdzie możemy dokonać ulepszeń. Bylibyśmy bardzo wdzięczni za poświęcenie kilku chwil na wypełnienie krótkiego formularza.

Formularz